209 related articles for article (PubMed ID: 32671914)
21. Expression Levels of Human Equilibrative Nucleoside Transporter 1 and Deoxycytidine Kinase Enzyme as Prognostic Factors in Patients with Acute Myeloid Leukemia Treated with Cytarabine.
Candelaria M; Corrales-Alfaro C; Gutiérrez-Hernández O; Díaz-Chavez J; Labardini-Méndez J; Vidal-Millán S; Herrera LA
Chemotherapy; 2016; 61(6):313-8. PubMed ID: 27119162
[TBL] [Abstract][Full Text] [Related]
22. Quantitative Targeted Proteomics of Pancreatic Cancer: Deoxycytidine Kinase Protein Level Correlates to Progression-Free Survival of Patients Receiving Gemcitabine Treatment.
Ohmine K; Kawaguchi K; Ohtsuki S; Motoi F; Ohtsuka H; Kamiie J; Abe T; Unno M; Terasaki T
Mol Pharm; 2015 Sep; 12(9):3282-91. PubMed ID: 26280109
[TBL] [Abstract][Full Text] [Related]
23. Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma.
Yamamoto M; Sanomachi T; Suzuki S; Uchida H; Yonezawa H; Higa N; Takajo T; Yamada Y; Sugai A; Togashi K; Seino S; Okada M; Sonoda Y; Hirano H; Yoshimoto K; Kitanaka C
Neuro Oncol; 2021 Jun; 23(6):945-954. PubMed ID: 33556172
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE
Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758
[TBL] [Abstract][Full Text] [Related]
25. Expression of nucleoside transporters and deoxycytidine kinase proteins in muscle invasive urothelial carcinoma of the bladder: correlation with pathological response to neoadjuvant platinum/gemcitabine combination chemotherapy.
North S; El-Gehani F; Santos C; Ghosh S; Lai R; Cass CE; Mackey JR
J Urol; 2014 Jan; 191(1):35-9. PubMed ID: 23851183
[TBL] [Abstract][Full Text] [Related]
26. Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer.
Komori S; Osada S; Mori R; Matsui S; Sanada Y; Tomita H; Tokuyama Y; Takahashi T; Yamaguchi K; Yoshida K
Pancreas; 2010 Nov; 39(8):1284-92. PubMed ID: 20944490
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival.
Sebastiani V; Ricci F; Rubio-Viqueira B; Kulesza P; Yeo CJ; Hidalgo M; Klein A; Laheru D; Iacobuzio-Donahue CA
Clin Cancer Res; 2006 Apr; 12(8):2492-7. PubMed ID: 16638857
[TBL] [Abstract][Full Text] [Related]
28. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.
Skrypek N; Duchêne B; Hebbar M; Leteurtre E; van Seuningen I; Jonckheere N
Oncogene; 2013 Mar; 32(13):1714-23. PubMed ID: 22580602
[TBL] [Abstract][Full Text] [Related]
29. dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Study.
Xiong J; Altaf K; Ke N; Wang Y; Tang J; Tan C; Li A; Zhang H; He D; Liu X
Medicine (Baltimore); 2016 Mar; 95(10):e2936. PubMed ID: 26962792
[TBL] [Abstract][Full Text] [Related]
30. Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC).
Santini D; Schiavon G; Vincenzi B; Cass CE; Vasile E; Manazza AD; Catalano V; Baldi GG; Lai R; Rizzo S; Giacobino A; Chiusa L; Caraglia M; Russo A; Mackey J; Falcone A; Tonini G
Curr Cancer Drug Targets; 2011 Jan; 11(1):123-9. PubMed ID: 20578980
[TBL] [Abstract][Full Text] [Related]
31. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
Nakagawa N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
Surgery; 2013 Apr; 153(4):565-75. PubMed ID: 23253379
[TBL] [Abstract][Full Text] [Related]
32. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients.
Mey V; Giovannetti E; De Braud F; Nannizzi S; Curigliano G; Verweij F; De Cobelli O; Pece S; Del Tacca M; Danesi R
Br J Cancer; 2006 Aug; 95(3):289-97. PubMed ID: 16868547
[TBL] [Abstract][Full Text] [Related]
33. A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers.
Wei CH; Gorgan TR; Elashoff DA; Hines OJ; Farrell JJ; Donahue TR
Pancreas; 2013 Nov; 42(8):1303-10. PubMed ID: 24152955
[TBL] [Abstract][Full Text] [Related]
34. Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase?
Funamizu N; Okamoto A; Kamata Y; Misawa T; Uwagawa T; Gocho T; Yanaga K; Manome Y
Oncol Rep; 2010 Feb; 23(2):471-5. PubMed ID: 20043109
[TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
Sugiyama E; Kaniwa N; Kim SR; Hasegawa R; Saito Y; Ueno H; Okusaka T; Ikeda M; Morizane C; Kondo S; Yamamoto N; Tamura T; Furuse J; Ishii H; Yoshida T; Saijo N; Sawada J
Clin Pharmacokinet; 2010 Aug; 49(8):549-58. PubMed ID: 20608756
[TBL] [Abstract][Full Text] [Related]
36. Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer.
Elebro J; Ben Dror L; Heby M; Nodin B; Jirström K; Eberhard J
Acta Oncol; 2016; 55(3):286-96. PubMed ID: 26362587
[TBL] [Abstract][Full Text] [Related]
37. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial.
Sinn M; Riess H; Sinn BV; Stieler JM; Pelzer U; Striefler JK; Oettle H; Bahra M; Denkert C; Bläker H; Lohneis P
Eur J Cancer; 2015 Aug; 51(12):1546-54. PubMed ID: 26049689
[TBL] [Abstract][Full Text] [Related]
38. Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma.
Vincenzi B; Stacchiotti S; Collini P; Pantano F; Rabitti C; Perrone G; Iuliani M; Baldi A; Badalamenti G; Sanfilippo R; Santini D; Muda AO; Gronchi A; Casali P; Dei Tos AP; Tonini G
Br J Cancer; 2017 Jul; 117(3):340-346. PubMed ID: 28641307
[TBL] [Abstract][Full Text] [Related]
39. Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients.
Tavano F; Fontana A; Pellegrini F; Burbaci FP; Rappa F; Cappello F; Copetti M; Maiello E; Lombardi L; Graziano P; Vinciguerra M; di Mola FF; di Sebastiano P; Andriulli A; Pazienza V
J Transl Med; 2014 Sep; 12():248. PubMed ID: 25199538
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles.
Lansakara-P DS; Rodriguez BL; Cui Z
Int J Pharm; 2012 Jun; 429(1-2):123-34. PubMed ID: 22425885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
